BioStock Investor Meeting: WntResearch presents
It has been an eventful quarter for WntResearch that develops the drug candidate Foxy-5 for the treatment of colon cancer. The company is currently conducting the phase IIb study NeoFox from which the company recently announced promising findings, causing a rally in the stock. The company’s CEO Pernilla Sandwall attended BioStock Investor Meeting and told us more about both the company and the new findings.
Watch WntResearch’s CEO Pernilla Sandwall present the company below:
